News

NovoCure gets FDA Not Approvable Letter for Optune Mya in lung-cancer brain metastases

What's the deal? NovoCure, a Swiss-headquartered medical device company, announced on 9 November 2026 that it received a Not Approvable Letter from the US Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya, its tumour-treating fields device, for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The FDA determined that uncertainty around the degree of clinical benefit prevented approval; it did not raise concerns about the device's safety profile.

Why it matters: Optune Mya delivers low-intensity electric fields (tumour-treating fields) through electrodes placed on the scalp to disrupt cancer cell division, and is currently approved for other brain-tumour indications. This decision blocks a new indication covering patients whose lung cancer has spread to the brain, a setting with high unmet need. NovoCure is evaluating the FDA's feedback and plans to meet with the agency to explore whether the application could support approval without additional clinical studies, noting there is no assurance these discussions will lead to approval.

Read more: NovoCure, 9 November 2026 · CancerNetwork, 10 November 2026

More top stories